StrokeNCT04116671
Stimulation Combined With Powered Motorized Orthoses for Walking After Stroke
A study testing Neuromechanical Gait Assist in people with Stroke and Hemiparesis, run by VA Office of Research and Development at 1 site in United States.
Trial summary
Objective: The goal of this study is to implement and test a neuro-mechanical gait assist (NMGA) device to correct walking characterized by muscle weakness, incoordination or excessive tone in Veterans with hemiparesis after stroke that adversely affects their ability to walk, exercise, perform activities of daily… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Stroke, Hemiparesis
- What is being tested?
- Neuromechanical Gait Assist
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Apr 2020to 1 Nov 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- More than 6 months post stroke
- Stiff-legged gait defined as a gait pattern manifesting as "dragging" or "catching" of the affected toes during swing phase of gait or use of compensatory strategies such as circumducting the affected limb, vaulting with the unaffected limb or hiking the affected hip
- Sufficient endurance and motor ability to ambulate at least 10 feet (ft) continuously with standby assist
- Weakness at the hip, knee and ankle
- Poor lower extremity coordination due to weakness or tone
- Hip extension range to neutral
Show all 9Show fewer
- Hip flexion range greater or equal to 90 degrees
- Passive range of ankle dorsiflexion to neutral with knee extended
- Sufficient upper extremity function to use a cane
Who cannot join
- Severe knee extensor tone requiring >25 newton meter (Nm) of torque to flex the knee
- Ankle contractures of more than 0 degrees of plantar flexion and hip contractures of greater than 0 degrees of hip flexion
- Inability to grasp with both hands
- History of potentially fatal cardiac arrhythmias such as ventricular tachycardia, supra-ventricular tachycardia, and rapid ventricular response atrial fibrillation with hemodynamic instability
- Presence of a demand pacemaker
- Parkinson's Disease
Show all 15Show fewer
- Edema of the affected limb
- Active pressure ulcers or wounds in lower extremities
- Sepsis or active infection
- Severe osteoporosis
- Uncontrolled seizures
- Presence of substance abuse
- Severely impaired cognition and communication
- Uncompensated hemineglect
- Pregnancy
Trial locations and contacts
1 site in 1 country.
United States1 site
Louis Stokes VA Medical Center, Cleveland, OH
Cleveland, Ohio, 44106-1702
About this study
Official title: Stimulation Combined With Externally Powered Motorized Orthoses for Stroke
Objective: The goal of this study is to implement and test a neuro-mechanical gait assist (NMGA) device to correct walking characterized by muscle weakness, incoordination or excessive tone in Veterans with hemiparesis after stroke that adversely affects their ability to walk, exercise, perform activities of daily living, and participate fully in personal, professional and social roles.
Research Plan: A prototype NMGA device will be used to develop a finite state controller (FSC) to coordinate each user's volitional effort with surface muscle stimulation and motorized knee assistance as needed. Brace mounted sensors will be used to develop a gait event detector (GED) which will serve the FSC to advance through the phases of gait or stair climbing. In addition, a rule-base intent detection algorithm will be developed using brace mounted sensors and user interface input to select among various functions including walking, stairs climbing, sit-to-stand and stand-to-sit maneuvers. The FSC controller tuning and intent algorithm development and evaluation will be on pilot subjects with difficulty walking after stroke. Outcome measures during development will provide specifications for a new prototype NMGA design which will be evaluated on pilot subjects to test the hypothesis that the NMGA improves walking speed, distance and energy consumption of walking. These baseline data and device will be used to design a follow-up clinical trial to measure orthotic impact of NMGA on mobility in activities of daily living at home and community.
Read more
Methodology: After meeting inclusion criteria, pilot subjects will undergo baseline gait evaluation with EMG activities of knee flexors and extensors, ankle plantar and dorsiflexors and isokinetic knee strength and passive resistance. They will be fitted with a NMGA combining a knee-ankle-foot-orthosis with a motorized knee joint and surface neuromuscular stimulation of plantar- and dorsi- flexors, vasti and rectus femoris. Brace mounted sensor data will be used for gait event detector (GED) algorithm development and evaluation. The GED will serve the FSC to proceed through phases of gait based on supervisory rule-based user intent recognition algorithm detected by brace mounted sensors and user input interface. The FSC will coordinate feed-forward control of tuned stimulation patterns and closed-loop controlled knee power assist as needed to control foot clearance during swing and stability of the knee during stance. Based on data attained during controller development and evaluation, a new prototype NMGA will be design, constructed and evaluated on pilot subjects to test the hypothesis that a NMGA device improves safety and stability, increases walking speed and distance and minimizes user effort.
Clinical Significance: The anticipated outcome is improved gait stability with improved swing knee flexion, thus, increasing the safety and preventing injurious falls of ambulatory individuals with hemiplegia due to stroke found in large and ever-increasing numbers in the aging Veteran population. Correcting gait should lead to improved quality of life and participation.
Read the detailed description
This study includes controller development and feasibility testing for a hybrid neuromuscular gait assist (NMGA) system to enhance walking after stroke. The study consists of baseline testing, fitting the device on participants, tuning assistance parameters to enhance walking, collecting movement data with and without the device, modifying controller designs to optimize walking, sit-to-stand transitions, and stair climbing, gait training, and evaluating movement capability with and without device assistance. Heart rate and blood pressure will be monitored during each session.
Device Description The NMGA is comprised of a motorized knee brace and surface electrical stimulation applied to muscles acting across the hip, knee, and ankle. The device is worn on the impaired side of the body with an orthotic interface attaching it to the leg. The goal of combining the powered knee with stimulation is to improve leg movement and coordination for safer walking at reduced user effort. The powered exoskeletal knee ensures adequate toe clearance during the swing phase of gait by generating knee flexion and then prevents knee buckling during the stance phase of gait by maintaining extension for support. Surface muscle stimulation assists with user volitional effort. Stimulation applied to ankle dorsiflexors assists with toe clearance during swing while quadriceps stimulation assists with stance. Gastrocnemius and rectus femoris stimulation assist with push-off and swing to improve walking speed.
This study focuses on developing and testing control methods that integrate assistance of stimulation and the powered knee with volitional activity in a manner that maximizes the user's own muscle contribution. Orthosis mounted sensors measure motion, joint angles, interaction forces and foot-floor contact to determine the current phase of gait and assistance required. A Gait Event Detector (GED) determines the phase of gait and appropriate control state based on sensor data and then a Finite State Controller (FSC) optimizes stimulation and motor assistance in coordination with volitional effort. The controller design incorporates feedforward control of stimulation with stimulation triggered by detection of different gait events. Feedback control is applied for motor assistance only as needed. This study will evaluate different algorithms to detect different phases of gait. Controller refinement is an iterative process of testing different algorithms, adjusting detection parameters, and adjusting assistance parameters.
In addition to detecting phases of gait during walking, this study will also develop algorithms to detect user intent for mobility task transitions. Beyond overground walking, mobility includes transitions between sitting and standing as well as stair climbing. Depending on command signal robustness, these transitions could be achieved through separate inputs (e.g. a smart phone app or orthosis mounted buttons) to inform the device when to change task states or may be detectable based on the user's motions. As part of this study the investigators will test different approaches to determine the safest effective option and user preferences.
The following describes the participation involved in this development process.
Screening After signing the informed consent form the subject will undergo screening to determine if an individual is eligible to participate in the study based on the inclusion/exclusion criteria. During screening the investigators will also collect information about stroke demographics (e.g. date of stroke, type of stroke, lesion location, side of impairment), medications, and leg and foot size to ensure the investigators have appropriately sized orthotic components during subsequent sessions.
Baseline testing After meeting all inclusion/exclusion criteria and agreeing to participate, initial testing will determine participants' impairment level and walking ability prior to controller development and training with the device. Walking tests will be completed in the laboratory, hospital hallways, and the environment surrounding the hospital. Outcomes will measure impairment in the legs, walking ability, and participants perceptions of the device and the effect on walking.
NMGA Fitting and Tuning The study team will work with the participant to fit the device and determine appropriate stimulation patterns to assist walking. Fitting includes choosing orthotic components that fit well on the wearer's leg and allow comfortable walking. Stimulation patterns will be generated for each individual. Electrodes will target movement at the hip, knee, and ankle on the affected side. During stimulation tuning the investigators will adjust surface stimulation electrode locations as well as stimulus timing and intensity during the gait cycle. Orthotic fitting and stimulation pattern creation are expected to take about two sessions. Assessments may be repeated with surface stimulation assistance.
Controller Development During several sessions, the participant will complete mobility tasks (i.e. walking, stair climbing, and sit-to-stand transitions) while walking with the NMGA and recording data to characterize walking (Quantitative Motion Analysis data and orthosis mounted sensor data). These data will be used to create and optimize the controller to estimate phases of gaits (e.g. initial contact, pre-swing, mid-swing) based on exoskeleton mounted sensors to coordinate NMGA assistance with walking ability. Participants will complete tasks while different algorithms control transitions between tasks (e.g. walking to stair climbing) and assistance during task completion. Controller parameters will be adjusted during this process to optimize assistance and determine which task transitions the sensors successfully detect and which transitions should be controlled by a separate user input. Contact guard assistance will be provided to prevent falls during controller development. During this process participants will be interviewed in an open discussion format to get feedback about aspects of the device that could be improved. Up to 16 sessions will be used for controller development.
Gait Training After determining a control algorithm, there will be six sessions of training to use the device for walking, stair climbing, and sit-to-stand transitions as appropriate. Gait training will be conducted by the study physical therapist in the gait laboratory, hospital hallways, and surrounding outdoor spaces. The physical therapist will provide standby assistance, monitor subjects' vital signs, record their progress and solicit feedback on the use of the NMGA. Training will focus on increasing walking speed while maintaining safety, specifically toe clearance in swing, stability in stance, and situational awareness to the surrounding environment. Participants will provide feedback about when during the process they feel comfortable donning, doffing, and using the device without study staff assistance. The study physical therapist will also provide input about when participants are capable of using the system independently.
Post-Training Assessment Following training with the NMGA, the previously described assessments (see Baseline Testing) will be repeated both with and without the device to test the hypothesis that walking with the NMGA compared to without enhances walking speed, endurance, metabolic consumption, and gait symmetry. In addition to the tests at baseline, participants will complete the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST), a survey to assess user satisfaction with a device. Additionally, each participant will fill out a worksheet prioritizing different design requirements (e.g. size, weight, ease of use). Up to six sessions will be used for final testing.
- Conditions
- Stroke, Hemiparesis
- Being tested
- Neuromechanical Gait Assist
- Keywords
- neuromuscular electrical stimulation, stroke, hemiparesis, walking, powered orthosis
- Medical subject headings
- Stroke, Paresis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neuromechanical Gait AssistDevice
Also called NMGA
A hybrid powered knee orthosis combined with surface muscle stimulation to assist walking.
| Study group | Role | What they receive |
|---|---|---|
| Neuromechanical Gait Assist | Experimental | All participants will participate in developing controllers to coordinate device assistance with walking ability. Walking will be compared before gait training and after gait training. Walking will be evaluated both with and without device assistance. Receives: Device: Neuromechanical Gait Assist |
What is being measured
The primary outcome is the main question the study is designed to answer.
Controller accuracy
The accuracy of the controller (True/False positives and negatives) in detecting gait events and gait transitions.
Measured: up to one year
Secondary outcomes (24)
10m walk test
The time required to walk 10m is measured to calculate walking speed.
Measured: At baseline
Quantitative motion analysis - kinematics
Participants complete mobility tasks in the laboratory (walking, stair ascent and descent, and sit-to-stand transitions). Body-worn and floor mounted sensors measure kinematics (i.e. motion).
Measured: At baseline
6 minute timed walk
The distance measured in 6 minutes of walking is measured.
Measured: At baseline
Oxygen consumption
Participants wear a face mask that measures oxygen consumption while they walk to determine the metabolic load of walking.
Measured: At baseline
Timed up and go test
This test of agility measures the time required to stand, walk a set distance, turn around, walk back, and sit down again.
Measured: At baseline
Manual Muscle Test
This test measures volitional strength at each joint (e.g. knee extension). A score is given based on the amount of movement at a joint and the resistance that can be applied. Scores for each movement range from 0 to 5. 0 is no muscle activation and 5 is normal strength.
Measured: At baseline
Modified Ashworth scale
This test measures spasticity. The joint is passively moved through its range of motion to determine muscle tightness in response to stretch. Scores range from 0 to 5. 0 is no increase in muscle tone while 5 indicates the joint is rigid.
Measured: At baseline
Fugl-Meyer Motor Assessment
This test measures coordination in combination with strength and spasticity. Individuals complete a series of movement and are scored based on their ability to complete each task. Scores range from 0 to 34. 0 indicates the worst possible movement and 34 indicates normal movement.
Measured: At baseline
Instrumented impairment measures - joint stiffness
These tests will be completed on a Biodex system. Participants will be seated with their leg attached to a force measurement device. The individual will remain relaxed while the device moves the joint through its range of motion.
Measured: At baseline
Instrumented impairment measures - strength
These tests will be completed on a Biodex system. Participants will be seated with their leg attached to a force measurement device. The individual will push with their leg to generate movement through a range of motion at different speeds (isokinetic test).
Measured: At baseline
Quantitative motion analysis - kinetics
Participants complete mobility tasks in the laboratory (walking, stair ascent and descent, and sit-to-stand transitions). Body-worn and floor mounted sensors measure kinetics (i.e. joint torques).
Measured: At baseline
Quantitative motion analysis - electromyograms
Participants complete mobility tasks in the laboratory (walking, stair ascent and descent, and sit-to-stand transitions). Body-worn sensors measure electromyograms (i.e. muscle activity).
Measured: At baseline
10m walk test
The time required to walk 10m is measured to calculate walking speed.
Measured: up to one year after baseline
6 minute timed walk
The distance measured in 6 minutes of walking is measured.
Measured: up to one year after baseline
Timed up and go test
This test of agility measures the time required to stand, walk a set distance, turn around, walk back, and sit down again.
Measured: up to one year after baseline
Quantitative motion analysis - kinematics
Participants complete mobility tasks in the laboratory (walking, stair ascent and descent, and sit-to-stand transitions). Body-worn and floor mounted sensors measure kinematics (i.e. motion).
Measured: up to one year after baseline
Oxygen consumption
Participants wear a face mask that measures oxygen consumption while they walk to determine the metabolic load of walking.
Measured: up to one year after baseline
Manual Muscle Test
This test measures volitional strength at each joint (e.g. knee extension). A score is given based on the amount of movement at a joint and the resistance that can be applied. Scores for each movement range from 0 to 5. 0 is no muscle activation and 5 is normal strength.
Measured: up to one year after baseline
Modified Ashworth scale
This test measures spasticity. The joint is passively moved through its range of motion to determine muscle tightness in response to stretch. Scores range from 0 to 5. 0 is no increase in muscle tone while 5 indicates the joint is rigid.
Measured: up to one year after baseline
Fugl-Meyer Motor Assessment
This test measures coordination in combination with strength and spasticity. Individuals complete a series of movement and are scored based on their ability to complete each task. Scores range from 0 to 34. 0 indicates the worst possible movement and 34 indicates normal movement.
Measured: up to one year after baseline
Instrumented impairment measures - joint stiffness
These tests will be completed on a Biodex system. Participants will be seated with their leg attached to a force measurement device. The individual will remain relaxed while the device moves the joint through its range of motion.
Measured: up to one year after baseline
Instrumented impairment measures - strength
These tests will be completed on a Biodex system. Participants will be seated with their leg attached to a force measurement device. The individual will push with their leg to generate movement through a range of motion at different speeds (isokinetic test).
Measured: up to one year after baseline
Quantitative motion analysis - kinetics
Participants complete mobility tasks in the laboratory (walking, stair ascent and descent, and sit-to-stand transitions). Body-worn and floor mounted sensors measure kinetics (i.e. joint torques).
Measured: up to one year after baseline
Quantitative motion analysis - electromyograms
Participants complete mobility tasks in the laboratory (walking, stair ascent and descent, and sit-to-stand transitions). Body-worn sensors measure electromyograms (i.e. muscle activity).
Measured: up to one year after baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Oct 2019
- Study start1 Apr 2020
- Primary completion1 Nov 2027 (estimated)
- Study completion1 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StrokeStudies of the same condition, open and under way.
- More trials run by VA Office of Research and DevelopmentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Participants are contributing to the development of a hybrid device combining surface muscle stimulation and a powered knee orthosis to assist walking after stroke. There is a single group of individuals participating in controller development and then pilot testing of the device to determine both the effect of training with the device and the impact of the device on walking ability.
- Masking
- None (open label)
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- VA Office of Research and Development
- Sponsor type
- US federal agency
- Responsible party
- Sponsor
- Investigators
- Ronald Triolo, PhD, Principal investigator, Louis Stokes VA Medical Center, Cleveland, OH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04116671
- Sponsor's protocol ID
- A3056-R
- Other IDs
- 5I01RX003056-02
- Status last verified
- Oct 2026
- First submitted
- 2 Oct 2019
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: De-identified data will be provided upon written request or as part of a journal publication. No personal identifiers or participant codes will be shared.
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Stimulation Combined With Externally Powered Motorized Orthoses for Stroke
- ClinicalTrials.gov ID
- NCT04116671
- Acronym / sponsor ID
- A3056-R
- Conditions
- Stroke, Hemiparesis
- Keywords
- neuromuscular electrical stimulation, stroke, hemiparesis, walking, powered orthosis
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 5 participants (actual)
- Lead sponsor
- VA Office of Research and DevelopmentUS federal agency
- Study start
- 1 Apr 2020 (actual)
- Primary completion
- 1 Nov 2027 (estimated)
- Study completion
- 1 Nov 2027 (estimated)
- First posted
- 4 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective: The goal of this study is to implement and test a neuro-mechanical gait assist (NMGA) device to correct walking characterized by muscle weakness, incoordination or excessive tone in Veterans with hemiparesis after stroke that adversely affects their ability to walk, exercise, perform activities of daily living, and participate fully in personal, professional and social roles.
Research Plan: A prototype NMGA device will be used to develop a finite state controller (FSC) to coordinate each user's volitional effort with surface muscle stimulation and motorized knee assistance as needed. Brace mounted sensors will be used to develop a gait event detector (GED) which will serve the FSC to advance through the phases of gait or stair climbing. In addition, a rule-base intent detection algorithm will be developed using brace mounted sensors and user interface input to select among various functions including walking, stairs climbing, sit-to-stand and stand-to-sit maneuvers. The FSC controller tuning and intent algorithm development and evaluation will be on pilot subjects with difficulty walking after stroke. Outcome measures during development will provide specifications for a new prototype NMGA design which will be evaluated on pilot subjects to test the hypothesis that the NMGA improves walking speed, distance and energy consumption of walking. These baseline data and device will be used to design a follow-up clinical trial to measure orthotic impact of NMGA on mobility in activities of daily living at home and community.
Methodology: After meeting inclusion criteria, pilot subjects will undergo baseline gait evaluation with EMG activities of knee flexors and extensors, ankle plantar and dorsiflexors and isokinetic knee strength and passive resistance. They will be fitted with a NMGA combining a knee-ankle-foot-orthosis with a motorized knee joint and surface neuromuscular stimulation of plantar- and dorsi- flexors, vasti and rectus femoris. Brace mounted sensor data will be used for gait event detector (GED) algorithm development and evaluation. The GED will serve the FSC to proceed through phases of gait based on supervisory rule-based user intent recognition algorithm detected by brace mounted sensors and user input interface. The FSC will coordinate feed-forward control of tuned stimulation patterns and closed-loop controlled knee power assist as needed to control foot clearance during swing and stability of the knee during stance. Based on data attained during controller development and evaluation, a new prototype NMGA will be design, constructed and evaluated on pilot subjects to test the hypothesis that a NMGA device improves safety and stability, increases walking speed and distance and minimizes user effort.
Clinical Significance: The anticipated outcome is improved gait stability with improved swing knee flexion, thus, increasing the safety and preventing injurious falls of ambulatory individuals with hemiplegia due to stroke found in large and ever-increasing numbers in the aging Veteran population. Correcting gait should lead to improved quality of life and participation.
Detailed description
This study includes controller development and feasibility testing for a hybrid neuromuscular gait assist (NMGA) system to enhance walking after stroke. The study consists of baseline testing, fitting the device on participants, tuning assistance parameters to enhance walking, collecting movement data with and without the device, modifying controller designs to optimize walking, sit-to-stand transitions, and stair climbing, gait training, and evaluating movement capability with and without device assistance. Heart rate and blood pressure will be monitored during each session.
Device Description The NMGA is comprised of a motorized knee brace and surface electrical stimulation applied to muscles acting across the hip, knee, and ankle. The device is worn on the impaired side of the body with an orthotic interface attaching it to the leg. The goal of combining the powered knee with stimulation is to improve leg movement and coordination for safer walking at reduced user effort. The powered exoskeletal knee ensures adequate toe clearance during the swing phase of gait by generating knee flexion and then prevents knee buckling during the stance phase of gait by maintaining extension for support. Surface muscle stimulation assists with user volitional effort. Stimulation applied to ankle dorsiflexors assists with toe clearance during swing while quadriceps stimulation assists with stance. Gastrocnemius and rectus femoris stimulation assist with push-off and swing to improve walking speed.
This study focuses on developing and testing control methods that integrate assistance of stimulation and the powered knee with volitional activity in a manner that maximizes the user's own muscle contribution. Orthosis mounted sensors measure motion, joint angles, interaction forces and foot-floor contact to determine the current phase of gait and assistance required. A Gait Event Detector (GED) determines the phase of gait and appropriate control state based on sensor data and then a Finite State Controller (FSC) optimizes stimulation and motor assistance in coordination with volitional effort. The controller design incorporates feedforward control of stimulation with stimulation triggered by detection of different gait events. Feedback control is applied for motor assistance only as needed. This study will evaluate different algorithms to detect different phases of gait. Controller refinement is an iterative process of testing different algorithms, adjusting detection parameters, and adjusting assistance parameters.
In addition to detecting phases of gait during walking, this study will also develop algorithms to detect user intent for mobility task transitions. Beyond overground walking, mobility includes transitions between sitting and standing as well as stair climbing. Depending on command signal robustness, these transitions could be achieved through separate inputs (e.g. a smart phone app or orthosis mounted buttons) to inform the device when to change task states or may be detectable based on the user's motions. As part of this study the investigators will test different approaches to determine the safest effective option and user preferences.
The following describes the participation involved in this development process.
Screening After signing the informed consent form the subject will undergo screening to determine if an individual is eligible to participate in the study based on the inclusion/exclusion criteria. During screening the investigators will also collect information about stroke demographics (e.g. date of stroke, type of stroke, lesion location, side of impairment), medications, and leg and foot size to ensure the investigators have appropriately sized orthotic components during subsequent sessions.
Baseline testing After meeting all inclusion/exclusion criteria and agreeing to participate, initial testing will determine participants' impairment level and walking ability prior to controller development and training with the device. Walking tests will be completed in the laboratory, hospital hallways, and the environment surrounding the hospital. Outcomes will measure impairment in the legs, walking ability, and participants perceptions of the device and the effect on walking.
NMGA Fitting and Tuning The study team will work with the participant to fit the device and determine appropriate stimulation patterns to assist walking. Fitting includes choosing orthotic components that fit well on the wearer's leg and allow comfortable walking. Stimulation patterns will be generated for each individual. Electrodes will target movement at the hip, knee, and ankle on the affected side. During stimulation tuning the investigators will adjust surface stimulation electrode locations as well as stimulus timing and intensity during the gait cycle. Orthotic fitting and stimulation pattern creation are expected to take about two sessions. Assessments may be repeated with surface stimulation assistance.
Controller Development During several sessions, the participant will complete mobility tasks (i.e. walking, stair climbing, and sit-to-stand transitions) while walking with the NMGA and recording data to characterize walking (Quantitative Motion Analysis data and orthosis mounted sensor data). These data will be used to create and optimize the controller to estimate phases of gaits (e.g. initial contact, pre-swing, mid-swing) based on exoskeleton mounted sensors to coordinate NMGA assistance with walking ability. Participants will complete tasks while different algorithms control transitions between tasks (e.g. walking to stair climbing) and assistance during task completion. Controller parameters will be adjusted during this process to optimize assistance and determine which task transitions the sensors successfully detect and which transitions should be controlled by a separate user input. Contact guard assistance will be provided to prevent falls during controller development. During this process participants will be interviewed in an open discussion format to get feedback about aspects of the device that could be improved. Up to 16 sessions will be used for controller development.
Gait Training After determining a control algorithm, there will be six sessions of training to use the device for walking, stair climbing, and sit-to-stand transitions as appropriate. Gait training will be conducted by the study physical therapist in the gait laboratory, hospital hallways, and surrounding outdoor spaces. The physical therapist will provide standby assistance, monitor subjects' vital signs, record their progress and solicit feedback on the use of the NMGA. Training will focus on increasing walking speed while maintaining safety, specifically toe clearance in swing, stability in stance, and situational awareness to the surrounding environment. Participants will provide feedback about when during the process they feel comfortable donning, doffing, and using the device without study staff assistance. The study physical therapist will also provide input about when participants are capable of using the system independently.
Post-Training Assessment Following training with the NMGA, the previously described assessments (see Baseline Testing) will be repeated both with and without the device to test the hypothesis that walking with the NMGA compared to without enhances walking speed, endurance, metabolic consumption, and gait symmetry. In addition to the tests at baseline, participants will complete the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST), a survey to assess user satisfaction with a device. Additionally, each participant will fill out a worksheet prioritizing different design requirements (e.g. size, weight, ease of use). Up to six sessions will be used for final testing.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Participants are contributing to the development of a hybrid device combining surface muscle stimulation and a powered knee orthosis to assist walking after stroke. There is a single group of individuals participating in controller development and then pilot testing of the device to determine both the effect of training with the device and the impact of the device on walking ability.
| Arm | Type | Receives |
|---|---|---|
| Neuromechanical Gait Assist | Experimental | Device: Neuromechanical Gait AssistAll participants will participate in developing controllers to coordinate device assistance with walking ability. Walking will be compared before gait training and after gait training. Walking will be evaluated both with and without device assistance. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- More than 6 months post stroke
- Stiff-legged gait defined as a gait pattern manifesting as "dragging" or "catching" of the affected toes during swing phase of gait or use of compensatory strategies such as circumducting the affected limb, vaulting with the unaffected limb or hiking the affected hip
- Sufficient endurance and motor ability to ambulate at least 10 feet (ft) continuously with standby assist
- Weakness at the hip, knee and ankle
- Poor lower extremity coordination due to weakness or tone
Key exclusion criteria (15 listed)
- Severe knee extensor tone requiring >25 newton meter (Nm) of torque to flex the knee
- Ankle contractures of more than 0 degrees of plantar flexion and hip contractures of greater than 0 degrees of hip flexion
- Inability to grasp with both hands
- History of potentially fatal cardiac arrhythmias such as ventricular tachycardia, supra-ventricular tachycardia, and rapid ventricular response atrial fibrillation with hemodynamic instability
- Presence of a demand pacemaker
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neuromechanical Gait AssistAlso: NMGAA hybrid powered knee orthosis combined with surface muscle stimulation to assist walking. | Device | Neuromechanical Gait Assist |
Primary outcome
Controller accuracy
Time frame: up to one year
The accuracy of the controller (True/False positives and negatives) in detecting gait events and gait transitions.
24 secondary outcomes
10m walk test
Time frame: At baseline
Quantitative motion analysis - kinematics
Time frame: At baseline
6 minute timed walk
Time frame: At baseline
Oxygen consumption
Time frame: At baseline
Timed up and go test
Time frame: At baseline
Manual Muscle Test
Time frame: At baseline
Modified Ashworth scale
Time frame: At baseline
Fugl-Meyer Motor Assessment
Time frame: At baseline
Instrumented impairment measures - joint stiffness
Time frame: At baseline
Instrumented impairment measures - strength
Time frame: At baseline
Quantitative motion analysis - kinetics
Time frame: At baseline
Quantitative motion analysis - electromyograms
Time frame: At baseline
10m walk test
Time frame: up to one year after baseline
6 minute timed walk
Time frame: up to one year after baseline
Timed up and go test
Time frame: up to one year after baseline
Quantitative motion analysis - kinematics
Time frame: up to one year after baseline
Oxygen consumption
Time frame: up to one year after baseline
Manual Muscle Test
Time frame: up to one year after baseline
Modified Ashworth scale
Time frame: up to one year after baseline
Fugl-Meyer Motor Assessment
Time frame: up to one year after baseline
Instrumented impairment measures - joint stiffness
Time frame: up to one year after baseline
Instrumented impairment measures - strength
Time frame: up to one year after baseline
Quantitative motion analysis - kinetics
Time frame: up to one year after baseline
Quantitative motion analysis - electromyograms
Time frame: up to one year after baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
- Individual participant dataSharing planned: No. De-identified data will be provided upon written request or as part of a journal publication. No personal identifiers or participant codes will be shared.
Related trials for Stroke
Recruiting
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
Stroke, Acute
RecruitingPhase 4
Xeomin® and Gait Related Mobility After Stroke
Stroke
RecruitingObservational study
Implementing Transcranial Direct Current Stimulation in a Rehabilitation Setting
Aphasia, Stroke
Not yet recruiting
EEG Feedback-Based Vagus Nerve Stimulation for Post-Stroke Dysphagia
Ischemic Stroke, Post-stroke Dysphagia
RecruitingObservational study
Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
Moyamoya Disease, Moyamoya Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ronald Triolo, PhD principal investigator
Louis Stokes VA Medical Center, Cleveland, OH
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Neuromechanical Gait Assist in people with Stroke and Hemiparesis, run by VA Office of Research and Development at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Controller accuracy (time frame: up to one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.